• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eyedrop Vaccination Induced Systemic and Mucosal Immunity against Influenza Virus in Ferrets

tetano

Editor, Senior Moderator
PLoS One. 2016 Jun 22;11(6):e0157634. doi: 10.1371/journal.pone.0157634. eCollection 2016.
[h=1]Eyedrop Vaccination Induced Systemic and Mucosal Immunity against Influenza Virus in Ferrets.[/h] Yoon S[SUP]1,[/SUP][SUP]2[/SUP], Kim ED[SUP]1,[/SUP][SUP]3[/SUP], Song MS[SUP]4[/SUP], Han SJ[SUP]1[/SUP], Park TK[SUP]5[/SUP], Choi KS[SUP]6[/SUP], Choi YK[SUP]4[/SUP], Seo KY[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] We investigated eyedrop vaccination (EDV) in pre-clinical development for immunological protection against influenza and for potential side effects involving ocular inflammation and the central nervous system (CNS). Live attenuated influenza EDV, CA07 (H1N1), PZ-4 (H1N2) and Uruguay (H3N2), induced both systemic and mucosal virus-specific antibody responses in ferrets. In addition, EDV resulted in a clinically significant protection against viral challenge, and suppression of viral replication in nasal secretion and lung tissue. Regarding safety, we found that administered EDV flow through the tear duct to reach the base of nasal cavity, and thus do not contact the olfactory bulb. All analyses for potential adverse effects due to EDV, including histological and functional examinations, did not reveal significant side effects. On the basis of these findings, we propose that EDV as effective, while being a safe administration route with minimum local side effects, CNS invasion, or visual function disturbance.


PMID: 27333331 [PubMed - in process] Free full text
 
Back
Top Bottom